

TRIPOD Checklist: Prediction Model Development

Section/Topic	Item	Checklist Item	Page
Title and abstract			
Title	1	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	1
Introduction			
Background and objectives	3a	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	2
	3b	Specify the objectives, including whether the study describes the development or validation of the model or both.	2
Methods			
Source of data	4a	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	2
	4b	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	2+3
Participants	5a	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	2+3
	5b	Describe eligibility criteria for participants.	2+3
	5c	Give details of treatments received, if relevant.	--
Outcome	6a	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	3+4
	6b	Report any actions to blind assessment of the outcome to be predicted.	3+4
Predictors	7a	Clearly define all predictors used in developing or validating the multivariable prediction model, including how and when they were measured.	3+4
	7b	Report any actions to blind assessment of predictors for the outcome and other predictors.	3+4
Sample size	8	Explain how the study size was arrived at.	3
Missing data	9	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	3+4
Statistical analysis methods	10a	Describe how predictors were handled in the analyses.	4
	10b	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	3+4
	10d	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	3+4
Risk groups	11	Provide details on how risk groups were created, if done.	2-4
Results			
Participants	13a	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	4+Fig.1
	13b	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	3-5 +Tab.1
Model development	14a	Specify the number of participants and outcome events in each analysis.	4-6
	14b	If done, report the unadjusted association between each candidate predictor and outcome.	7
Model specification	15a	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	4-6 +Fig.2
	15b	Explain how to use the prediction model.	4-9
Model performance	16	Report performance measures (with CIs) for the prediction model.	6-8 +Tab.2+3
Discussion			
Limitations	18	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	8+9
Interpretation	19b	Give an overall interpretation of the results, considering objectives, limitations, and results from similar studies, and other relevant evidence.	8+9
Implications	20	Discuss the potential clinical use of the model and implications for future research.	9
Other information			
Supplementary information	21	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	9
Funding	22	Give the source of funding and the role of the funders for the present study.	9